{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:19Z","timestamp":1792785019252,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008171","name":"Target Ovarian Cancer","doi-asserted-by":"publisher","award":["Edinburgh-CG19"],"award-info":[{"award-number":["Edinburgh-CG19"]}],"id":[{"id":"10.13039\/501100008171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IGC Langmuir Talent Fellowship","award":["RLH-22"],"award-info":[{"award-number":["RLH-22"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023452","name":"Hanarth Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023452","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly understood. Recent data suggest some of these molecular features may be biomarkers of response to recently introduced biologically-targeted therapies, namely endocrine therapy and MEK inhibitors. We utilize a cohort of 63 pathologically-confirmed LGSOC cases with whole exome sequencing and hormone receptor expression data to investigate these relationships. LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progesterone receptor (PR) expression intensity. 60% and 37% of cases demonstrated micropapillary and macropapillary patterns of stromal invasion, respectively. 63% of cases demonstrated desmoplasia, which was significantly associated with advanced disease stage and visible residual disease after cytoreductive surgery. MAPK-mutant cases (\n                    <jats:italic>KRAS<\/jats:italic>\n                    ,\n                    <jats:italic>BRAF<\/jats:italic>\n                    ,\n                    <jats:italic>NRAS<\/jats:italic>\n                    ) more frequently demonstrated macropapillary stromal invasion, while Chr1p loss was associated with desmoplasia and low PR expression. Presence of micropapillary stromal invasion and low PR expression were associated with significantly poorer survival after accounting for stage and residual disease status. Together, these data identify novel relationships between histopathological features and molecularly-defined subgroups in LGSOC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-34627-5","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:02:05Z","timestamp":1683795725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Robert L.","family":"Hollis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"van Baal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narthana","family":"Ilenkovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Churchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"van de Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Meynert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzyvia","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Croy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon","family":"van Gent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Creedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Nirsimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Simon","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"34627_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","volume":"156","author":"B Slomovitz","year":"2020","unstructured":"Slomovitz, B. et al. Low-grade serous ovarian cancer: State of the science. Gynecol. Oncol. 156, 715\u2013725. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.033 (2020).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR2","doi-asserted-by":"publisher","first-page":"216057","DOI":"10.1016\/j.canlet.2023.216057","volume":"555","author":"RL Hollis","year":"2023","unstructured":"Hollis, R. L. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 555, 216057. https:\/\/doi.org\/10.1016\/j.canlet.2023.216057 (2023).","journal-title":"Cancer Lett."},{"key":"34627_CR3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-4183","author":"B Manning-Geist","year":"2022","unstructured":"Manning-Geist, B. et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4183 (2022).","journal-title":"Clin. Cancer Res."},{"key":"34627_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","volume":"165","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M. et al. The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes. Gynecol. Oncol. 165, 560\u2013567. https:\/\/doi.org\/10.1016\/j.ygyno.2021.11.019 (2022).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5545","volume":"253","author":"D Cheasley","year":"2021","unstructured":"Cheasley, D. et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J. Pathol. 253, 41\u201354. https:\/\/doi.org\/10.1002\/path.5545 (2021).","journal-title":"J. Pathol."},{"key":"34627_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.3967","volume":"226","author":"S Jones","year":"2012","unstructured":"Jones, S. et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J. Pathol. 226, 413\u2013420. https:\/\/doi.org\/10.1002\/path.3967 (2012).","journal-title":"J. Pathol."},{"key":"34627_CR7","doi-asserted-by":"publisher","first-page":"37663","DOI":"10.18632\/oncotarget.5438","volume":"6","author":"SM Hunter","year":"2015","unstructured":"Hunter, S. M. et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6, 37663\u201337677. https:\/\/doi.org\/10.18632\/oncotarget.5438 (2015).","journal-title":"Oncotarget"},{"key":"34627_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.09.022","author":"A ElNaggar","year":"2022","unstructured":"ElNaggar, A. et al. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy. Gynecol. Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.022 (2022).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615. https:\/\/doi.org\/10.1038\/nature10166 (2011).","journal-title":"Nature"},{"key":"34627_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0179-8","author":"G Macintyre","year":"2018","unstructured":"Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-018-0179-8 (2018).","journal-title":"Nat. Genet."},{"key":"34627_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh, W. et al. Hormone-receptor expression and ovarian cancer survival: An Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 14, 853\u2013862. https:\/\/doi.org\/10.1016\/s1470-2045(13)70253-5 (2013).","journal-title":"Lancet Oncol."},{"key":"34627_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","volume":"157","author":"M Llaurado Fernandez","year":"2020","unstructured":"Llaurado Fernandez, M. et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Gynecol. Oncol. 157, 12\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.029 (2020).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica, A. et al. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 28, 496\u2013504. https:\/\/doi.org\/10.1097\/00000478-200404000-00009 (2004).","journal-title":"Am. J. Surg. Pathol."},{"key":"34627_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","volume":"140","author":"JP Grabowski","year":"2016","unstructured":"Grabowski, J. P. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol. Oncol. 140, 457\u2013462. https:\/\/doi.org\/10.1016\/j.ygyno.2016.01.022 (2016).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","volume":"108","author":"KM Schmeler","year":"2008","unstructured":"Schmeler, K. M. et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 108, 510\u2013514. https:\/\/doi.org\/10.1016\/j.ygyno.2007.11.013 (2008).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl Cancer Inst. 111, 60\u201368. https:\/\/doi.org\/10.1093\/jnci\/djy071 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"34627_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s1470-2045(20)30591-x","volume":"22","author":"RD Morgan","year":"2021","unstructured":"Morgan, R. D. et al. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): Post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 22, 277\u2013288. https:\/\/doi.org\/10.1016\/s1470-2045(20)30591-x (2021).","journal-title":"Lancet Oncol."},{"key":"34627_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668\u2013679. https:\/\/doi.org\/10.1038\/nrc4019 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"34627_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong, D. K. et al. NCCN guidelines\u00ae insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 20, 972\u2013980. https:\/\/doi.org\/10.6004\/jnccn.2022.0047 (2022).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"34627_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/jco.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson, D. M. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J. Clin. Oncol. 35, 1103\u20131111. https:\/\/doi.org\/10.1200\/jco.2016.71.0632 (2017).","journal-title":"J. Clin. Oncol."},{"key":"34627_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","volume":"147","author":"AN Fader","year":"2017","unstructured":"Fader, A. N. et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. Gynecol. Oncol. 147, 85\u201391. https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.127 (2017).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","volume":"125","author":"DM Gershenson","year":"2012","unstructured":"Gershenson, D. M. et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 125, 661\u2013666. https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.037 (2012).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","volume":"154","author":"M Tang","year":"2019","unstructured":"Tang, M. et al. PARAGON: A phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecol. Oncol. 154, 531\u2013538. https:\/\/doi.org\/10.1016\/j.ygyno.2019.06.011 (2019).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ygyno.2018.11.030","volume":"152","author":"B Stanley","year":"2019","unstructured":"Stanley, B. et al. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecol. Oncol. 152, 278\u2013285. https:\/\/doi.org\/10.1016\/j.ygyno.2018.11.030 (2019).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR25","first-page":"2233","volume":"8","author":"A Bowman","year":"2002","unstructured":"Bowman, A. et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8, 2233\u20132239 (2002).","journal-title":"Clin. Cancer Res."},{"key":"34627_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M. et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): An international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet 399, 541\u2013553. https:\/\/doi.org\/10.1016\/s0140-6736(21)02175-9 (2022).","journal-title":"Lancet"},{"key":"34627_CR27","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/jco.20.01164","volume":"38","author":"BJ Monk","year":"2020","unstructured":"Monk, B. J. et al. MILO\/ENGOT-ov11: Binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38, 3753\u20133762. https:\/\/doi.org\/10.1200\/jco.20.01164 (2020).","journal-title":"J. Clin. Oncol."},{"key":"34627_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020458","author":"A Babaier","year":"2022","unstructured":"Babaier, A., Mal, H., Alselwi, W. & Ghatage, P. Low-grade serous carcinoma of the ovary: The current status. Diagnostics https:\/\/doi.org\/10.3390\/diagnostics12020458 (2022).","journal-title":"Diagnostics"},{"key":"34627_CR29","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/PAS.0b013e318181a7ce","volume":"32","author":"A Yemelyanova","year":"2008","unstructured":"Yemelyanova, A., Mao, T. L., Nakayama, N., Shih Ie, M. & Kurman, R. J. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am. J. Surg. Pathol. 32, 1800\u20131806. https:\/\/doi.org\/10.1097\/PAS.0b013e318181a7ce (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"34627_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ygyno.2012.04.029","volume":"126","author":"I Diaz-Padilla","year":"2012","unstructured":"Diaz-Padilla, I. et al. Ovarian low-grade serous carcinoma: A comprehensive update. Gynecol. Oncol. 126, 279\u2013285. https:\/\/doi.org\/10.1016\/j.ygyno.2012.04.029 (2012).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR31","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/pas.0000000000001245","volume":"43","author":"I Alvarado-Cabrero","year":"2019","unstructured":"Alvarado-Cabrero, I. et al. Micropapillary cervical adenocarcinoma: A clinicopathologic study of 44 cases. Am. J. Surg. Pathol. 43, 802\u2013809. https:\/\/doi.org\/10.1097\/pas.0000000000001245 (2019).","journal-title":"Am. J. Surg. Pathol."},{"key":"34627_CR32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1309\/xtj7-vhb4-9ud7-8x60","volume":"121","author":"G Pettinato","year":"2004","unstructured":"Pettinato, G., Manivel, C. J., Panico, L., Sparano, L. & Petrella, G. Invasive micropapillary carcinoma of the breast: Clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am. J. Clin. Pathol. 121, 857\u2013866. https:\/\/doi.org\/10.1309\/xtj7-vhb4-9ud7-8x60 (2004).","journal-title":"Am. J. Clin. Pathol."},{"key":"34627_CR33","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/00000478-199412000-00005","volume":"18","author":"MB Amin","year":"1994","unstructured":"Amin, M. B. et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am. J. Surg. Pathol. 18, 1224\u20131232. https:\/\/doi.org\/10.1097\/00000478-199412000-00005 (1994).","journal-title":"Am. J. Surg. Pathol."},{"key":"34627_CR34","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/modpathol.2008.79","volume":"21","author":"K Kamiya","year":"2008","unstructured":"Kamiya, K. et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod. Pathol. 21, 992\u20131001. https:\/\/doi.org\/10.1038\/modpathol.2008.79 (2008).","journal-title":"Mod. Pathol."},{"key":"34627_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/pas.0000000000000615","volume":"40","author":"E Okoye","year":"2016","unstructured":"Okoye, E., Euscher, E. D. & Malpica, A. Ovarian low-grade serous carcinoma: A clinicopathologic study of 33 cases with primary surgery performed at a single institution. Am. J. Surg. Pathol. 40, 627\u2013635. https:\/\/doi.org\/10.1097\/pas.0000000000000615 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"34627_CR36","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.Ccr-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott, C. J. et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 21, 3561\u20133568. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1051 (2015).","journal-title":"Clin. Cancer Res."},{"key":"34627_CR37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-22-0004","author":"M Llaurado Fernandez","year":"2022","unstructured":"Llaurado Fernandez, M. et al. NOTCH signaling limits the response of low grade serous ovarian cancers to MEK inhibition. Mol. Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0004 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"34627_CR38","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1158\/0008-5472.Can-20-2222","volume":"81","author":"R Shrestha","year":"2021","unstructured":"Shrestha, R. et al. multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Cancer Res. 81, 1681\u20131694. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2222 (2021).","journal-title":"Cancer Res."},{"key":"34627_CR39","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1158\/1535-7163.Mct-22-0004","volume":"21","author":"M Llaurado Fernandez","year":"2022","unstructured":"Llaurado Fernandez, M. et al. NOTCH signaling limits the response of low-grade serous ovarian cancers to MEK inhibition. Mol. Cancer Ther. 21, 1862\u20131874. https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0004 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"34627_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41698-021-00187-y","volume":"5","author":"RL Hollis","year":"2021","unstructured":"Hollis, R. L. et al. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. NPJ Precis. Oncol. 5, 47. https:\/\/doi.org\/10.1038\/s41698-021-00187-y (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"34627_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ygyno.2019.09.001","volume":"155","author":"RL Hollis","year":"2019","unstructured":"Hollis, R. L. et al. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma. Gynecol. Oncol. 155, 318\u2013323. https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.001 (2019).","journal-title":"Gynecol. Oncol."},{"key":"34627_CR42","doi-asserted-by":"publisher","first-page":"CD015048","DOI":"10.1002\/14651858.CD015048.pub2","volume":"9","author":"A Bryant","year":"2022","unstructured":"Bryant, A. et al. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst. Rev. 9, CD015048. https:\/\/doi.org\/10.1002\/14651858.CD015048.pub2 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"key":"34627_CR43","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/1471-0528.16264","volume":"127","author":"A Irodi","year":"2020","unstructured":"Irodi, A. et al. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG 127, 1409\u20131420. https:\/\/doi.org\/10.1111\/1471-0528.16264 (2020).","journal-title":"BJOG"},{"key":"34627_CR44","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41416-022-01874-8","volume":"127","author":"RL Hollis","year":"2022","unstructured":"Hollis, R. L. et al. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. Br. J. Cancer 127, 1034\u20131042. https:\/\/doi.org\/10.1038\/s41416-022-01874-8 (2022).","journal-title":"Br. J. Cancer"},{"key":"34627_CR45","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.3390\/cancers13225839","volume":"13","author":"RL Hollis","year":"2021","unstructured":"Hollis, R. L. et al. Clinicopathological determinants of recurrence risk and survival in mucinous ovarian carcinoma. Cancers 13, 5839 (2021).","journal-title":"Cancers"},{"key":"34627_CR46","doi-asserted-by":"publisher","first-page":"20012","DOI":"10.1038\/s41598-020-77075-1","volume":"10","author":"J-H Kang","year":"2020","unstructured":"Kang, J.-H. et al. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: Experiences at two large academic institutions in Korea and Taiwan. Sci. Rep. 10, 20012. https:\/\/doi.org\/10.1038\/s41598-020-77075-1 (2020).","journal-title":"Sci. Rep."},{"key":"34627_CR47","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jmig.2022.05.016","volume":"29","author":"MC Di Donna","year":"2022","unstructured":"Di Donna, M. C. et al. Laparoscopic ultra-radical lymph node debulking using yasargil clamps for gynecological malignancies: Results from a large, multicenter, retrospective analysis. J. Minim Invasive Gynecol. 29, 1083\u20131091. https:\/\/doi.org\/10.1016\/j.jmig.2022.05.016 (2022).","journal-title":"J. Minim Invasive Gynecol."},{"key":"34627_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000525126","volume":"87","author":"S Uccella","year":"2022","unstructured":"Uccella, S. et al. Cervical versus utero-ovarian ligament injection of the tracer for the pelvic sentinel lymph node mapping in gynecologic oncology: A prospective observational study. Gynecol. Obstet. Investig. 87, 242\u2013247. https:\/\/doi.org\/10.1159\/000525126 (2022).","journal-title":"Gynecol. Obstet. Investig."},{"key":"34627_CR49","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/0008-5472.Can-16-2224","volume":"77","author":"D Etemadmoghadam","year":"2017","unstructured":"Etemadmoghadam, D. et al. EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas. Cancer Res. 77, 4268\u20134278. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-2224 (2017).","journal-title":"Cancer Res."},{"key":"34627_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.01.22270258","author":"JP Thomson","year":"2022","unstructured":"Thomson, J. P. et al. Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma identifies clinically distinct disease subtypes. medRxiv https:\/\/doi.org\/10.1101\/2022.02.01.22270258 (2022).","journal-title":"medRxiv"},{"key":"34627_CR51","doi-asserted-by":"crossref","unstructured":"Thomson, J. P. et al. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Gynecol. Oncol. 2023 (in press)","DOI":"10.1016\/j.ygyno.2023.04.011"},{"key":"34627_CR52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2559.2006.02412.x","volume":"48","author":"T Kirkegaard","year":"2006","unstructured":"Kirkegaard, T. et al. Observer variation in immunohistochemical analysis of protein expression, time for a change?. Histopathology 48, 787\u2013794. https:\/\/doi.org\/10.1111\/j.1365-2559.2006.02412.x (2006).","journal-title":"Histopathology"},{"key":"34627_CR53","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/PAS.0b013e318181a7ce","volume":"32","author":"A Yemelyanova","year":"2008","unstructured":"Yemelyanova, A., Mao, T. L., Nakayama, N., Shih, I. M. & Kurman, R. J. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am. J. Surg. Pathol. 32, 1800\u20131806. https:\/\/doi.org\/10.1097\/PAS.0b013e318181a7ce (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"34627_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13059-015-0617-1","volume":"16","author":"T Kuilman","year":"2015","unstructured":"Kuilman, T. et al. CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol. 16, 49. https:\/\/doi.org\/10.1186\/s13059-015-0617-1 (2015).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34627-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:25:53Z","timestamp":1702387553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34627-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34627"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34627-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RLH: consultancy fees from GlaxoSmithKline and DeciBio. CG: research funding from AstraZeneca, MSD, Novartis, Aprea, Nucana, GSK, BerGen Bio, Medannexin, Artios; honoraria\/consultancy fees from AstraZeneca, MSD, GSK, Clovis, Chugai, Cor2Ed, Takeda, Eisai, Peer Voice; named on issued\/pending patents related to predicting treatment response in ovarian cancer outside the scope of the work described here. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7681"}}